CIK 0001593899 · Non-accelerated filer<br>Smaller reporting company
Atea Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AVIR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- operating
- EIN
- 460574869
- Phone
- (857) 284-8891
- Business address
- 225 FRANKLIN STREET, SUITE 2100, BOSTON, MA, 02110
- DEFA14A Proxy Proxy Materials
- DFAN14A Other Proxy Soliciting Materials
- DEFA14A Proxy Proxy Materials
- 8-K Event Other events
- SCHEDULE 13D/A Stake Beneficial Ownership Report
- 10-K Report Annual Report
- 8-K Event Results of operations
- SCHEDULE 13D Stake Beneficial Ownership Report
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 8-K Event Executive or director change
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Shares withheld for taxes Chief Development Officer gave up 14,134 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Commercial Officer gave up 11,517 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Medical Officer gave up 16,071 shares (to pay taxes)
- 4 Shares withheld for taxes See Remarks gave up 16,102 shares (to pay taxes)
- 4 Shares withheld for taxes President, CEO, and Chairman gave up 88,601 shares (to pay taxes)
- 4 Shares withheld for taxes EVP, Chief Accounting Officer gave up 12,062 shares (to pay taxes)
- 4/A Open-market buy Director bought 25,000 shares at an average $3.26 ($81,499)
- 4 Open-market buy Director bought 25,000 shares at an average $3.26 ($81,499)
Page 4 of 16 · 316 filings